Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study

Schwarz, L.; Spiliotis, John; Akaishi, Eduardo Hiroshi; Goèré, Diane; Sugarbaker, Paul H.; Baratti, Dario; Quénet, François; Bartlett, David L.; Villeneuve, Laurent; Képénékian, Vahan; Ahrendt, Steven A.; Baik, Seung Hyuk; Bhatt, A.; Cachin, P.; Ceelen, Wim; Hingh, Ignace de; Simone, Michele De; Dubé, Pierre; Edwards, Robert P.; Franko, Jan; González-Bayón, L.; Gushchin, Vadim; Holtzman, Matthew P.; Hsieh, Mao‐Chih; Kecmanović, Dragutin; Lee, K.W.; Lehmann, Kuno; Levine, Edward A.; Liu, Y.; Mehta, Sanket; Morris, David L.; O’Dwyer, Sarah T; Orsenigo, E.; Pande, Pankaj; Park, E.J.; Pingpank, James F.; Piso, Pompiliu; Rajan, Firoz; Rau, Beate; Sardi, Armando; Sidéris, Lucas; Sommariva, Antonio; Tentes, Antonios Apostolos; Teo, Melissa Ching Ching; Yarema, Roman; Yonemura, Yutaka; Younan, Rami; Zaveri, Shabber; Zeh, H.; Abba, J.; Abboud, Karine; Alyami, Mohammad; Arvieux, C.; Bakrin, Naoual; Béréder, Jean-Marc; Bouzard, D.; Brigand, Cécile; Carrère, Sébastien; Delroeux, Delphine; Dumont, Frédéric; Eveno, Clarisse; Facy, Olivier; Guyon, Frédéric; Ferron, Gwénaël; Gléhen, Olivier; Kianmanesh, Réza; Dico, R. Lo; Lorimier, G.; Marchal, Frédéric; Mariani, Pascale; Méeus, Pierre; Msika, Simon; Ortega‐Deballon, Pablo; Paquette, Brice; Passot, Guillaume; Peyrat, Patrice; Pirrò, N.; Pocard, Marc; Porcheron, J.; Rat, Patrick; Sgarbură, Olivia; Thibaudeau, Emilie; Tuech, J.‐J.; Zinzindohoué, Franck

doi:10.1016/j.ejso.2018.05.021

Cited by 31 publications

(17 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, according to Lin's study, synchronous PM of HCC had a median OS of 3.8 months, significantly worse than metachronous PM. However, this patient had a progression-free survival (PFS) of over 16 months, which may indicate the important role of CRS+HIPEC in the treatment of HCC with PM, as Mehta et al [3] reported. Second, a diffuse PM with PCI of 30 underwent incomplete CRS+HIPEC had an incredible PFS compared to an OS of 5.9 months reported in Mehta's study.…”

Section: Discussionmentioning

confidence: 90%

“…The prognosis of HCCPM is very poor, with a median survival of 6 to 14 months treated with Sorafenib and/or systemic chemotherapy. [3] Several groups reported the role of aggressive surgical management for HCCPM [3,5–10] (Table 1). These works suggest that active cytoreduction if the patient's condition could tolerate major surgery, could bring bigger benefit than other treatment options.…”

Section: Discussionmentioning

confidence: 99%

“…They concluded that CRS+HIPEC is a safe and effective approach in selected patients with PM of HCC. [3]…”

Section: Discussionmentioning

confidence: 99%

“…There has been no standard treatment for HCCPM, and the conventional palliative therapy could only reach an overall survival (OS) of 6 to 14 months. [3] There is an urgent need for innovative treatment of HCCPM.…”

Section: Introductionmentioning

confidence: 99%

“…Some small sample cohort studies have reported that CRS+HIPEC could improve the median OS of HCCPM. [3,4] However, the role of CRS+HIPEC in treating HCCPM needs to be verified.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Long-term progression-free survival of hepatocellular carcinoma with synchronous diffuse peritoneal metastasis treated by CRS+HIPEC

et al. 2019

Medicine

View full text Add to dashboard Cite

Rationale: Hepatocellular carcinoma (HCC) with peritoneal metastasis (PM) is rare. There has been no standard treatment for this severe disease, and the conventional palliative therapy could only reach an overall survival of 6 to 14 months Patient concerns: A 38-year-old male with a chief complain of “abdominal distension and diagnosis of HCCPM for 3 months”, was suffering from severe diarrhea and moderate anemia. Diagnosis: Diagnostic laparoscopic exploration with biopsy and the following pathology confirmed the diagnosis of HCC with PM. Interventions: The patient was treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) followed by 6 cycles of intraperitoneal chemotherapy and 6 cycles of intravenous chemotherapy. Outcomes: Till January 15, 2019, the patient has progression-free survival for over 22 months. Lessons: CRS plus HIPEC combined adjuvant intraperitoneal and intravenous chemotherapy may improve progression-free survival for some HCC with PM patients and should be considered as an option for such patients.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

“…They concluded that CRS+HIPEC is a safe and effective approach in selected patients with PM of HCC. [3]…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Some small sample cohort studies have reported that CRS+HIPEC could improve the median OS of HCCPM. [3,4] However, the role of CRS+HIPEC in treating HCCPM needs to be verified.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Long-term progression-free survival of hepatocellular carcinoma with synchronous diffuse peritoneal metastasis treated by CRS+HIPEC

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

New metastasectomy criteria for peritoneal metastasis of hepatocellular carcinoma: A study of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery

Iida

Tani

Aihara

et al. 2020

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

Among extrahepatic metastases of hepatocellular carcinoma (HCC), the incidence rate of peritoneal metastasis (6%-11%) is much lower than the lung, bone, lymph node, or adrenal gland metastasis rates. 1,2 HCC larger than 5 cm, the presence of vascular invasion, a positive resection margin, poorly differentiated HCC, and radiofrequency ablation on HCC near the liver surface are considered to be risk factors for peritoneal metastasis. 3,4 HCC treatment guidelines in Japan recommend systemic chemotherapy, that is, treatment with molecular

show abstract

Therapeutische Optionen bei peritonealer Metastasierung hepatopankreatikobiliärer Tumoren und neuroendokriner Tumoren

et al. 2022

View full text Add to dashboard Cite

Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study

Cited by 31 publications

References 41 publications

Long-term progression-free survival of hepatocellular carcinoma with synchronous diffuse peritoneal metastasis treated by CRS+HIPEC

Long-term progression-free survival of hepatocellular carcinoma with synchronous diffuse peritoneal metastasis treated by CRS+HIPEC

New metastasectomy criteria for peritoneal metastasis of hepatocellular carcinoma: A study of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery

Therapeutische Optionen bei peritonealer Metastasierung hepatopankreatikobiliärer Tumoren und neuroendokriner Tumoren

Contact Info

Product

Resources

About